FDA Approves TERLIVAZ — Mallinckrodt Hospital Products Inc.

Mallinckrodt Hospital Products Inc. announced FDA approval of the intravenous drug TERLIPRESSIN (Generic: TERLIPRESSIN), a significant milestone for the company’s hospital portfolio that is poised to bolster revenue amidst an ongoing competitive pricing war in the acute care therapeutic space. This approval for App # NDA022231 strengthens Mallinckrodt’s positioning in the critical care sector, potentially offsetting recent generic settlement pressure and enhancing the company's financial outlook.